COST-EFFECTIVENESS ANALYSIS OF ROSUVASTATIN COMPARED TO ATORVASTATIN IN SPANISH PATIENTS AT MODERATE, HIGH, AND VERY HIGH CARDIOVASCULAR RISK

被引：0
|
作者：
Garcia-Goni, M. [1 ]
Facila, L. [2 ]
Cinza, S. [3 ]
Pinto, X. [4 ]
Cortes, X. [5 ]
Prades, M. [6 ]
Aceituno, S. [6 ]
机构：
[1] Univ Complutense, Madrid, Spain
[2] Hosp Gen Univ Valencia, Valencia, Spain
[3] Porto Do Son Primary Care Hlth Ctr, La Coruna, Spain
[4] Hosp Bellvitge Princeps Espanya, Lhospitalet De Llobregat, Spain
[5] Almirall SA, Barcelona, Spain
[6] Outcomes 10, Castellon De La Plana, Spain
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.09.620
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCV74
引用
收藏
页码：S104 / S105
页数：3
相关论文
共 50 条
  • [1] Cost-effectiveness of rosuvastatin versus simvastatin, atorvastatin and pitavastatin in patients with high and very high cardiovascular risk in Spain
    Cosin Sales, Juan
    Fuentes Jimenez, Francisco Jose
    Mantilla Morato, Teresa
    Ruiz, Emilio
    Becerra, Virginia
    Aceituno, Susana
    Giovanna Ferrario, Maria
    Lizan, Luis
    Gracia, Alfredo
    CLINICA E INVESTIGACION EN ARTERIOSCLEROSIS, 2015, 27 (05): : 228 - 238
  • [2] COST-EFFECTIVENESS ANALYSIS OF ROSUVASTATIN VERSUS GENERIC ATORVASTATIN IN PATIENTS AT HIGH CARDIOVASCULAR RISK IN SPAIN
    Brosa, M.
    Barrios, V
    Lobos, J. M.
    Serrano, A.
    Capel, M.
    Alvarez, C.
    VALUE IN HEALTH, 2011, 14 (07) : A380 - A380
  • [3] Cost-effectiveness of rosuvastatin in comparison with generic atorvastatin and simvastatin in a Swedish population at high risk of cardiovascular events
    Gandhi, Sanjay K.
    Jensen, Marie M.
    Fox, Kathleen M.
    Smolen, Lee
    Olsson, Anders G.
    Paulsson, Thomas
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2012, 4 : 1 - 11
  • [4] Effectiveness and cost-effectiveness of rosuvastatin, atorvastatin, and simvastatin among high-risk patients in usual clinical practice
    Ohsfeldt, Robert L.
    Gandhi, Sanjay K.
    Fox, Kathleen M.
    Stacy, Thomas A.
    McKenney, James M.
    AMERICAN JOURNAL OF MANAGED CARE, 2006, 12 (15): : S412 - S423
  • [5] Cost-effectiveness analysis of rosuvastatin compared to atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin
    Benner, JS
    Smith, TW
    Klingman, D
    Tierce, JC
    Mullins, CD
    Pethick, N
    O'Donnell, J
    VALUE IN HEALTH, 2004, 7 (03) : 323 - 323
  • [6] Cost-effectiveness of rosuvastatin for cardiovascular prevention in high-risk populations in Sweden
    Jonsson, L.
    Ekman, M.
    Karlsson, G.
    Brun, J.
    VALUE IN HEALTH, 2006, 9 (06) : A346 - A346
  • [7] Updated Cost-effectiveness Analysis of Evolocumab in Patients With Very High-risk Atherosclerotic Cardiovascular Disease
    Fonarow, Gregg C.
    van Hout, Ben
    Villa, Guillermo
    Arellano, Jorge
    Lindgren, Peter
    JAMA CARDIOLOGY, 2019, 4 (07) : 691 - 695
  • [8] COST-EFFECTIVENESS ANALYSIS OF ALIROCUMAB IN HIGH CARDIOVASCULAR-RISK PATIENTS IN ITALY
    Povero, M.
    Pradelli, L.
    Fanelli, F.
    Gazzi, L.
    Serra, A.
    VALUE IN HEALTH, 2020, 23 : S490 - S490
  • [9] Cost-effectiveness analysis of alirocumab in high cardiovascular-risk patients in Italy
    Povero, Massimiliano
    Pradelli, Lorenzo
    Serra, Andrea
    Fanelli, Francesca
    Gazzi, Luca
    FARMECONOMIA-HEALTH ECONOMICS AND THERAPEUTIC PATHWAYS, 2021, 22 (01)
  • [10] COST-EFFECTIVENESS OF EVOLOCUMAB IN PATIENTS WITH HIGH CARDIOVASCULAR RISK IN SPAIN
    Villa, G.
    Lothgren, M.
    Kutikova, L.
    Lindgren, P.
    Gandra, S. R.
    Fonarow, G. C.
    Sorio, F.
    Masana, L.
    Bayes-Genis, A.
    van Hout, B.
    VALUE IN HEALTH, 2016, 19 (07) : A651 - A652
12345